CAPR Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of --. Capricor Therapeutics's return on equity of -75.99% beat Armata Pharmaceuticals's return on equity of --.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 288.57%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 469.11%. Given that Armata Pharmaceuticals has higher upside potential than Capricor Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.651, which suggesting that the stock is 365.145% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Capricor Therapeutics's net income of -$7.1M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 17.79x versus 445.83x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -63.94% compared to Capricor Therapeutics's net margin of --. Capricor Therapeutics's return on equity of -75.99% beat Perspective Therapeutics's return on equity of --.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 288.57%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 641.9%. Given that Perspective Therapeutics has higher upside potential than Capricor Therapeutics, analysts believe Perspective Therapeutics is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.651, which suggesting that the stock is 365.145% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Capricor Therapeutics's net income of -$7.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 17.79x versus 12.56x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 0.18%. Capricor Therapeutics's return on equity of -75.99% beat Envista Holdings's return on equity of -32.33%.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 288.57%. On the other hand Envista Holdings has an analysts' consensus of $20.25 which suggests that it could grow by 33.4%. Given that Capricor Therapeutics has higher upside potential than Envista Holdings, analysts believe Capricor Therapeutics is more attractive than Envista Holdings.

Capricor Therapeutics has a beta of 4.651, which suggesting that the stock is 365.145% more volatile than S&P 500. In comparison Envista Holdings has a beta of 1.120, suggesting its more volatile than the S&P 500 by 12.044%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Capricor Therapeutics's net income of -$7.1M is lower than Envista Holdings's net income of $1.2M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 17.79x versus 1.04x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 35.65%. Capricor Therapeutics's return on equity of -75.99% beat Protalix BioTherapeutics's return on equity of 8.75%.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 288.57%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 455.56%. Given that Protalix BioTherapeutics has higher upside potential than Capricor Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.651, which suggesting that the stock is 365.145% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Capricor Therapeutics's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 87.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 17.79x versus 4.06x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.